Explore this recorded session from the American Diabetes Association’s 2026 Scientific Sessions on amylin-based therapies for obesity and diabetes, featuring research on amylin’s biology and brain mechanisms, clinical trial findings, and potential benefits and limitations. Hear how these treatments may be used alone or alongside GLP-1 therapies, future roles in obesity care, and open questions for research and clinical practice.